Sun J, Du L, Yan L, et al. - Researchers sought to determine antimicrobial resistance profiles change in uropathogenic Escherichia coli (UPEC) during an 8-year period, particularly extended-spectrum β-lactamase (ESBL)-producing and carbapenem-resistant isolates. In this retrospective observational study of urinary tract infections (UTIs), they identified 7,713 non-repetitive UPEC isolates; of these, 7,075 (91.7%) were from inpatients and 638 (8.3%) were from outpatients. Observations revealed a decline in the prevalence of ESBL from 62.5% to 49.7%. Except for cefoxitin, they observed mostly higher resistance rates of ESBL-producing isolates vs that of non-ESBL-producing isolates. There was a slight decline in resistance rates of ampicillin, ampicillin/sulbactam, ceftriaxone, gentamycin, tobramycin, and trimethoprim/sulfamethoxazole, while a slight increase was noted in the resistance rate of imipenem. The prevalence of carbapenem-resistant Escherichia coli was < 2.0%. Findings suggest that the main drug-resistant bacteria causing UTIs is still ESBL-producing Escherichia coli. Attention should be paid to antimicrobial resistance in high-risk inpatient areas and effective measures should be taken to prevent and control nosocomial infections.